Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;40(2):327-334.
doi: 10.1007/s00345-021-03889-x. Epub 2021 Dec 2.

Clinical characteristics, treatment patterns and relapse in patients with clinical stage IS testicular cancer

Maximilian Peter Brandt  1 , C Ruf  2 , K P Dieckmann  3 , I Syring  4 , C Ruckes  5 , T Nestler  6 , H U Schmelz  6 , R Dotzauer  7 , A Hiester  8 , P Albers  8 , D Nettersheim  9 , C Bolenz  10 , S H Loosen  11 , A Heidenreich  12 , D Pfister  12 , A Haferkamp  7 , F Zengerling #  10 , P Paffenholz #  12 ; GESRU Academics Testis, Penile Cancer Group
Collaborators, Affiliations

Clinical characteristics, treatment patterns and relapse in patients with clinical stage IS testicular cancer

Maximilian Peter Brandt et al. World J Urol. 2022 Feb.

Abstract

Purpose: Clinical stage I (CSI) testicular germ cell tumors (TGCT) represents disease confined to the testis without metastasis and CSIS is defined as persistently elevated tumor markers (TM) after orchiectomy, indicating subclinical metastatic disease. This study aims at assessing clinical characteristics and oncological outcome in CSIS.

Methods: Data from five tertiary referring centers in Germany were screened. We defined correct classification of CSIS according to EAU guidelines. TM levels, treatment and relapse-free survival were assessed and differences between predefined groups (chemotherapy, correct/incorrect CSIS) were analyzed with Fisher's exact and Chi-square test.

Results: Out of 2616 TGCT patients, 43 (1.6%) were CSIS. Thereof, 27 were correctly classified (cCSIS, 1.03%) and 16 incorrectly classified (iCSIS). TMs that defined cCSIS were in 12 (44.4%), 10 (37%), 3 (11.1%) and 2 (7.4%) patients AFP, ß-HCG, AFP plus ß-HCG and LDH, respectively. In the cCSIS group, six patients were seminoma and 21 non-seminoma. Treatment consisted of active surveillance, carboplatin-mono AUC7 and BEP (bleomycin, etoposide and cisplatin). No difference between cCSIS and iCSIS with respect to applied chemotherapy was found (p = 0.830). 5-year relapse-free survival was 88.9% and three patients (11%) in the cCSIS group relapsed. All underwent salvage treatment (3xBEP) with no documented death.

Conclusion: Around 1% of all TGCT were classified as cCSIS patients. Identification of cCSIS is of critical importance to avoid disease progression and relapses by adequate treatment. We report a high heterogeneity of treatment patterns, associated with excellent long-term survival irrespective of the initial treatment approach.

Keywords: Chemotherapy; Clinical stage IS; Non-seminoma; Seminoma; Tumor markers.

PubMed Disclaimer

Conflict of interest statement

The authors declare they have no financial or competing interests.

Figures

Fig. 1
Fig. 1
Flow chart of the screened patients
Fig. 2
Fig. 2
Kaplan–Meier plot of relapse probability in the correctly classified CSIS cohort
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Albers P, et al. Guidelines on testicular cancer: 2015 update. Eur Urol. 2015;68(6):1054–1068. doi: 10.1016/j.eururo.2015.07.044. - DOI - PubMed
    1. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K.) (2019) AWMF, S3-Leitlinie Diagnostik, Therapie und Nachsorge der Keimzelltumoren des Hodens. 2019 (Langversion 1.0)
    1. Kamran SC, et al. Contemporary treatment patterns and outcomes for clinical stage IS testicular cancer. Eur Urol. 2018;73(2):262–270. doi: 10.1016/j.eururo.2017.06.013. - DOI - PubMed
    1. Faber KD, et al. Validation of surveillance, epidemiology, and end results TNM staging for testicular germ cell tumor. Urol Oncol. 2014;32(h8):1341–1346. doi: 10.1016/j.urolonc.2014.04.004. - DOI - PubMed
    1. Wymer KM, et al. Mildly elevated serum alpha-fetoprotein (AFP) among patients with testicular cancer may not be associated with residual cancer or need for treatment. Ann Oncol. 2017;28(4):899–902. doi: 10.1093/annonc/mdx012. - DOI - PubMed

MeSH terms